Olaparib Tablets

A drug used to treat adults with certain types of prostate cancer, pancreatic cancer, breast cancer, or ovarian, fallopian tube, or primary peritoneal cancer. It is also being studied in the treatment of other types of cancer. Olaparib blocks an enzyme involved in many cell functions, including the repair of DNA damage. Blocking this enzyme may help keep cancer cells from repairing their damaged DNA, causing them to die. Olaparib is a type of PARP inhibitor. Also called AZD2281, Lynparza, and PARP inhibitor AZD2281. US Brand Name(s): Lynparza. FDA Approved: Yes

Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers. Olaparib is indicated to treat breast cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, pancreatic cancer, and prostate cancer.

Olaparib is approved to treat:

• Breast cancer that is HER2 negative and has certain germline mutations in the BRCA1 or BRCA2 gene.
• Ovarian cancer that has certain germline mutations in the BRCA1 or BRCA2 gene and is advanced. Olaparib is used in adults who have already been treated with at least three other types of chemotherapy.
• Ovarian epithelial, fallopian tube, or primary peritoneal cancer. Olaparib is used as maintenance therapy in adults who are having a complete or partial response to platinum chemotherapy.
• Pancreatic cancer. Olaparib is used as maintenance therapy in adults with metastatic cancer that has not progressed after first-line therapy with platinum chemotherapy and has certain germline mutations in the BRCA1 or BRCA2 gene.
• Prostate cancer that is metastatic, has germline or somatic mutations in certain genes involved in the homologous recombination repair pathway, and is castrate resistant (has not responded to treatments that lower testosterone levels). Olaparib is used in adults whose cancer has gotten worse after treatment with enzalutamide or abiraterone.